Bumetanide

General Toxicity Notes
Natriuretic drugs may cause extracellular fluid volume depletion.
Excreted Unchanged %
33
Half-Life (Normalesrd) Hours
1.2-1.5/1.5
Plasma Protein Binding %
96
Volume Of Distribution L/Kg
0.2-0.5
Dose For Normal Renal Function
1-2 mg q8-12h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None
Supplement For Dialysis [Recommendation Level]: Pd
PD: None
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable, [D]
References
Lau HS, Hyneck ML, Berardi RR, Swartz RD, Smith DE. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure. Clin Pharmacol Ther. 1986; 39: 635-45. [PMID: 3709028] / Pentik&#246; inen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Penttil&#246; A. Bumetanide kinetics in renal failure. Clin Pharmacol Ther. 1985; 37: 582-8. [PMID: 3987182] / Ward A, Heel RC. Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs. 1984; 28: 426-64. [PMID: 6391889]
Toxicity Notes
Ototoxicity increased in ESRD in combination with aminoglycosides. High doses effective in ESRD. Muscle pain; gynecomastia.